Dasatinib treatment reduced MDR1 and Survivin expression levels to the same extent in all resistant cells compared to the parental HS-Sultan cells (Fig. 4e, f), indicating that Src inhibition could restore drug sensitivity by reducing overexpression of MDR1 and Survivin in acquired drug-resistant BL cells. The gene discussed is SRC; the disease is Burkitt lymphoma.